Stay updated with breaking news from Lal Pathlabs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The week gone by was highly volatile, with Nifty gaining 2.2% or 490 points in four sessions and hitting a lifetime high of 23,000. The week was also in the news for block deals involving over three dozen companies from large, mid and smallcap segments worth Rs 13,059 crore on screen.
Sun Pharma numbers were slightly below expectations in terms of EBITDA and we do think that though they have guided for a very strong growth through their speciality portfolio, that is a little bit time away.
This resurgence is expected to be fuelled by increased testing, strategic price adjustments, expansion of wellness services, says report by HDFC Securities
Lal said that the private sector can collaborate with the government in providing services where the state-run hospitals are found to be lacking
Emkay is bullish on Dr Lal Pathlabs has recommended buy rating on the stock with a target price of Rs 2800 in its research report dated May 10, 2024.